(© Kateryna_Kon - stock.adobe.com)
BRISTOL, United Kingdom — Researchers have finally cracked a half-century-old mystery in the world of blood science. A team of scientists from NHS Blood and Transplant and the University of Bristol has discovered a new blood group called MAL, shedding light on a puzzling antigen that has baffled experts since the 1970s.
This discovery isn’t just academic — it has real-world implications for patients with rare blood types and could revolutionize how we approach blood transfusions for some of our most vulnerable patients.
The Elusive AnWj Antigen
At the heart of this scientific detective story is the AnWj antigen, a tiny marker on the surface of red blood cells. First identified in 1972, AnWj has been a persistent enigma in the blood research community. While most people have this antigen, a select few don’t — and that’s where things get interesting.
“The genetic background of AnWj has been a mystery for more than 50 years,” explains Louise Tilley, a senior research scientist at NHS Blood and Transplant, in a media release. “It represents a huge achievement, and the culmination of a long team effort, to finally establish this new blood group system and be able to offer the best care to rare, but important, patients.”
A Needle in a Haystack
Finding people without the AnWj antigen is like searching for a needle in a haystack — they’re incredibly rare. In fact, more than 99.9% of people are AnWj-positive. The research team identified only five genetically AnWj-negative individuals in their study, including a family of Arab-Israelis.
One of the samples tested came from a woman who gave blood in 2015 — the same person who was the first AnWj-negative individual discovered in the 1970s. Talk about a full-circle moment in scientific research!
The Hunt for Answers
So, how did the team finally solve this long-standing mystery? They used a technique called whole exome sequencing — essentially, a deep dive into the parts of our DNA that code for proteins. This high-tech approach allowed them to identify specific deletions in a gene called MAL, which is responsible for producing the Mal protein.
To prove their theory, the researchers performed a clever experiment. They introduced the normal MAL gene into cells and observed that it produced the AnWj antigen. When they tried the same thing with the mutated version of the gene, no AnWj antigen appeared. This was the smoking gun they needed to confirm their discovery.
Why It Matters
You might be wondering why all this fuss over a rare blood type is important. The answer lies in the critical nature of blood transfusions. When patients receive blood that doesn’t match their own, it can lead to serious, even life-threatening reactions.
“Now genotyping tests can be designed to identify genetically AnWj-negative patients and donors. Such tests can be added to the existing genotyping platforms,” says Dr. Nicole Thornton, Head of Red Cell Reference at NHS Blood and Transplant.
In simpler terms, this discovery allows doctors to more accurately match blood for transfusions, potentially saving lives in the process.
The Bigger Picture
While ABO and Rh factors are the blood types we’re most familiar with, our blood is far more complex. The MAL system is now the 47th blood group system to be discovered, highlighting just how intricate our biology really is.
“It’s really exciting we were able [to] use our ability to manipulate gene expression in the developing blood cells to help confirm the identity of the AnWj blood group, which has been an outstanding puzzle for half a century. This development will help identify these rare donors and help patients in the future,” notes Professor Ash Toye from the University of Bristol.
Looking Ahead
As with many scientific breakthroughs, this discovery opens up new avenues for research and medical applications. The team’s findings, published in the prestigious journal Blood, pave the way for developing new tests to identify rare blood types and reduce the risk of transfusion complications.
In the end, this story is a testament to the persistence of scientific inquiry. It took 50 years, cutting-edge technology, and a dedicated team of researchers to solve this blood-type mystery. But with each discovery like this, we move one step closer to safer, more effective medical treatments for everyone.
Paper Summary
Methodology
The researchers began by collecting blood samples from individuals with the rare AnWj-negative blood type and their families. They used a variety of genetic testing techniques, such as whole exome sequencing, to examine their DNA. This helped them identify missing parts of the MAL gene, which produces a protein called Mal. To confirm that this deletion caused the AnWj-negative blood type, they also conducted tests on more people with this blood type. Further laboratory work involved experimenting with cells to observe the role of Mal protein in expressing the AnWj antigen, using techniques like flow cytometry and confocal microscopy, which are ways of visualizing cells.
Key Results
The study discovered that people with the AnWj-negative blood type all shared a specific deletion in the MAL gene, leading to a lack of Mal protein in their red blood cells. This protein is essential for the presence of the AnWj antigen, so without it, these individuals were AnWj-negative. They also proved that the Mal protein, not the previously suspected CD44 protein, is necessary for the expression of this antigen. When Mal protein was artificially introduced into lab-grown cells, the AnWj antigen appeared, confirming that the two are directly linked.
Study Limitations
While the study provided strong evidence that the deletion in the MAL gene causes the AnWj-negative blood type, the researchers were not able to test everyone who might have this condition. Additionally, they could not determine the exact cause for people with a temporary absence of the AnWj antigen. The study was also limited by the fact that they only observed certain aspects of the cells in controlled laboratory environments, which might differ from how these processes happen in the body.
Discussion & Takeaways
The study solved a decades-old mystery about the genetic cause of the AnWj-negative blood type. They showed that the MAL gene is critical for producing the Mal protein, which is necessary for the expression of the AnWj antigen. This new understanding can help in blood transfusions, especially for people who are AnWj-negative, as they may develop harmful antibodies if given AnWj-positive blood. Importantly, the findings lay the groundwork for further research on blood types and related genetic mutations.
Funding & Disclosures
This research was funded by NHS Blood and Transplant (NHSBT) and other partners, including the Saudi Ministry of Education and the National Institute for Health Research. Some authors disclosed their involvement with Scarlet Therapeutics Ltd., a biotechnology company, where they serve as consultants or directors.
